John Aizlewood

Kicking ketamine: strategies for sobriety

John Aizlewood is CEO of Broadway Lodge, the UK’s longest-established rehab for addiction. It has been treating clients with ketamine problems and he will bring that coalface experience to delegates at DB Recovery+UKESAD.

He is also chair of Choices Rehabs, earned through his many years of experience gained in the charitable, healthcare, retail and fundraising sectors as well as experience working in large corporations specialising in hospitality and finance.

John brings a passion for developing and growing businesses sustainably, focusing on both the services offered as well as employee development.

John will co-present with Lee Ali.

PRESENTATION

Ketamine – what are its impacts

Acquire a comprehensive overview of ketamine – a substance that has transitioned from a clinical anesthetic to a widely discussed recreational drug and emerging therapeutic tool. Medically, it serves as an anesthetic and shows promise in treating treatment-resistant depression and other mental health conditions. Recreationally, users seek its euphoric, dissociative “K-hole” experiences, sensory distortions, and temporary escape from reality. Short-term impacts include euphoria, detachment from body and environment, hallucinations, impaired coordination, elevated heart rate and blood pressure, nausea, and risks of injury due to reduced pain perception. Long-term and chronic use can incur severe physical consequences such as ketamine-associated cystitis (bladder damage that can lead to surgical intervention), “K-cramps”, nasal damage from snorting, cognitive impairments, mood disorders, anxiety, depression and psychological dependence Attendees will gain a balanced, evidence-based understanding of its pharmacology, rising popularity, profound effects on users, and the unique challenges it poses for recovery support.

Learning Objectives

At the end of this presentation, delegates will be able to:
  • Discuss why ketamine use is growing, drawing on epidemiological trends, cultural shifts, and self-medication drivers
  • Disseminate insights into what its use does to the user, including detailed short- and long-term physical, psychological and neurological impacts
  • Define what programmes are doing to support clients, recognising how ketamine recovery pathways differ from those for other substances and identifying best practices for effective intervention.